SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization

SciSparc Ltd. ( (SPRC) ) just unveiled an update.

On January 26, 2026, SciSparc Ltd. closed the acquisition of the full portfolio of patents, trademarks, know-how and related intellectual property from Xylo Technologies Ltd., centered on innovative endoscopic systems and medical cameras, including the MUSE single-use device for minimally invasive transoral fundoplication to treat gastroesophageal reflux disease (GERD). As consideration, SciSparc issued Xylo a stake equivalent to 19.99% of its outstanding share capital in ordinary shares, partly in the form of pre-funded warrants, and signaled that it will move immediately to commercialize the MUSE technology and associated devices, aiming to tap into a GERD device market estimated at $2.5 billion in 2024 and projected to grow to $3.03 billion by 2030; the deal marks a strategic expansion beyond SciSparc’s existing cannabinoid drug-development focus into medical devices, potentially diversifying its revenue streams and leveraging Xylo’s prior commercialization success in Greater China as a template for distribution partnerships in North America, Europe and Latin America.

More about SciSparc Ltd.

SciSparc Ltd. is a Nasdaq-listed, Israel-based company that, through its majority-owned subsidiary NeuroThera Labs Inc., is engaged in clinical-stage pharmaceutical development focused on cannabinoid-based therapeutics. Its pipeline includes THC- and CBD-based drug candidates such as SCI-110 for Tourette syndrome and Alzheimer’s-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus, and it also holds a controlling interest in a subsidiary selling hemp seed oil-based products on Amazon’s marketplace.

Average Trading Volume: 2,064,660

Technical Sentiment Signal: Sell

Current Market Cap: $4.39M

For an in-depth examination of SPRC stock, go to TipRanks’ Overview page.